Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 pediatric safety and pharmacokinetic study of berotralstat prophylaxis in hereditary angioedema
2024-511257-22-00Phase 3Authorised
- Sponsor
- BioCryst Pharmaceuticals, Inc.
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 3, open-label, single-arm trial of berotralstat in hereditary angioedema (HAE), sponsored by BioCryst Pharmaceuticals, Inc. Primary endpoint: Pharmacokinetic profile of berotralstat. Planned start Sep 2024; status: authorised.
02
Drugs
berotralstat
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on 2024-511257-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511257-22-00.